The technology quantifies the efficacy of genome-editing methods and identifies the predominant types of insertions and deletions in a targeted pool of cells.
The seven-parameter proposal potentially offers a way to assess how the immune system and a cancer interact on a broader level in order to better guide treatment.
NEW YORK (GenomeWeb News) – A group of Dutch-led research partners will use a €1.2 million ($1.5 million) grant awarded under a collaboration with Stand Up 2 Cancer (SU2C) to fund a genomics-based project seeking to use tumor profiles to predict patient response to cancer treatments.
"We will use multiple 'omics' technologies to ask which kinase signaling pathways are activated in colon cancer," an Agendia spokesperson said of the collaboration, which will also provide independent validation of the company's ColoPrint colon cancer recurrence test.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
